Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals

Mass production of low-cost, generic direct-acting antivirals (DAAs) will be required to achieve targets of eliminating hepatitis C (HCV) by 2030. The pharmaceutical companies Gilead and Bristol-Myers Squibb have granted voluntary licences (VLs) to generic companies to mass produce the DAAs sofosbuv...

Descripción completa

Detalles Bibliográficos
Autores principales: Hill, Andrew, Tahat, Loai, Mohammed, Mohammed Khalil, Tayyem, Rabab Fayez, Khwairakpam, Giten, Nath, Sanjay, Freeman, James, Benbitour, Ismahane, Helmy, Sherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mediscript Ltd 2018
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892672/
https://www.ncbi.nlm.nih.gov/pubmed/29682307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892672/
https://www.ncbi.nlm.nih.gov/pubmed/29682307

Ejemplares similares